Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.

Vaishampayan U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner JL, Stark K, Smith D, Heath EI, Fontana J, Shields AF.

Clin Cancer Res. 2018 Oct 16. pii: clincanres.1473.2018. doi: 10.1158/1078-0432.CCR-18-1473. [Epub ahead of print]

PMID:
30327304
2.

Catch and Release Photosensitizers: Combining Dual Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Arora K, Herroon M, Al-Afyouni MH, Toupin NP, Rohrabaugh TN Jr, Loftus LM, Podgorski I, Turro C, Kodanko JJ.

J Am Chem Soc. 2018 Oct 2. doi: 10.1021/jacs.8b08853. [Epub ahead of print]

PMID:
30278123
3.

Adenoviruses of the most ancient primate lineages support the theory on virus-host co-evolution.

Podgorski II, Pantó L, Földes K, de Winter I, Jánoska M, Sós E, Chenet B, Harrach B, Benkő M.

Acta Vet Hung. 2018 Sep;66(3):474-487. doi: 10.1556/004.2018.042.

PMID:
30264611
4.

Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis.

Kalpage HA, Bazylianska V, Recanati MA, Fite A, Liu J, Wan J, Mantena N, Malek MH, Podgorski I, Heath EI, Vaishnav A, Edwards BF, Grossman LI, Sanderson TH, Lee I, Hüttemann M.

FASEB J. 2018 Sep 17:fj201801417R. doi: 10.1096/fj.201801417R. [Epub ahead of print]

PMID:
30222078
5.

Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L.

Huisman M, Kodanko JP, Arora K, Herroon M, Alnaed M, Endicott J, Podgorski I, Kodanko JJ.

Inorg Chem. 2018 Jul 2;57(13):7881-7891. doi: 10.1021/acs.inorgchem.8b00978. Epub 2018 Jun 8.

6.

The Lipid Side of Bone Marrow Adipocytes: How Tumor Cells Adapt and Survive in Bone.

Diedrich JD, Herroon MK, Rajagurubandara E, Podgorski I.

Curr Osteoporos Rep. 2018 Aug;16(4):443-457. doi: 10.1007/s11914-018-0453-9. Review.

PMID:
29869753
7.

De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment.

Pinterić M, Podgorski II, Sobočanec S, Popović Hadžija M, Paradžik M, Dekanić A, Marinović M, Halasz M, Belužić R, Davidović G, Ambriović Ristov A, Balog T.

Free Radic Res. 2018 Jun;52(6):672-684. doi: 10.1080/10715762.2018.1462495. Epub 2018 Apr 23.

PMID:
29683756
8.

Polysialic acid is a cellular receptor for human adenovirus 52.

Lenman A, Liaci AM, Liu Y, Frängsmyr L, Frank M, Blaum BS, Chai W, Podgorski II, Harrach B, Benkő M, Feizi T, Stehle T, Arnberg N.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4264-E4273. doi: 10.1073/pnas.1716900115. Epub 2018 Apr 19.

9.

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun L, Bolton S, Bock CH.

Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.

PMID:
29471417
10.

Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin.

Herroon MK, Rajagurubandara E, Diedrich JD, Heath EI, Podgorski I.

Sci Rep. 2018 Jan 8;8(1):40. doi: 10.1038/s41598-017-17800-5.

11.

Loss of ABHD5 promotes the aggressiveness of prostate cancer cells.

Chen G, Zhou G, Aras S, He Z, Lucas S, Podgorski I, Skar W, Granneman JG, Wang J.

Sci Rep. 2017 Oct 12;7(1):13021. doi: 10.1038/s41598-017-13398-w.

12.

Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.

Li A, Yadav R, White JK, Herroon MK, Callahan BP, Podgorski I, Turro C, Scott EE, Kodanko JJ.

Chem Commun (Camb). 2017 Mar 28;53(26):3673-3676. doi: 10.1039/c7cc01459g.

13.

Caging the uncageable: using metal complex release for photochemical control over irreversible inhibition.

Huisman M, White JK, Lewalski VG, Podgorski I, Turro C, Kodanko JJ.

Chem Commun (Camb). 2016 Oct 18;52(85):12590-12593.

14.

Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation.

Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, Hüttemann M, Podgorski I.

Oncotarget. 2016 Oct 4;7(40):64854-64877. doi: 10.18632/oncotarget.11712.

15.

New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells.

Herroon MK, Diedrich JD, Podgorski I.

Front Endocrinol (Lausanne). 2016 Jul 6;7:84. doi: 10.3389/fendo.2016.00084. eCollection 2016.

16.

Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression.

Chkourko Gusky H, Diedrich J, MacDougald OA, Podgorski I.

Obes Rev. 2016 Nov;17(11):1015-1029. doi: 10.1111/obr.12450. Epub 2016 Jul 19. Review.

17.

Genome analysis of four Old World monkey adenoviruses supports the proposed species classification of primate adenoviruses and reveals signs of possible homologous recombination.

Podgorski II, Pantó L, Papp T, Harrach B, Benkö M.

J Gen Virol. 2016 Jul;97(7):1604-14. doi: 10.1099/jgv.0.000465. Epub 2016 Mar 24.

PMID:
27010199
18.

Photoactivated inhibition of cathepsin K in a 3D tumor model.

Herroon MK, Sharma R, Rajagurubandara E, Turro C, Kodanko JJ, Podgorski I.

Biol Chem. 2016 Jun 1;397(6):571-82. doi: 10.1515/hsz-2015-0274.

19.

Selective Release of Aromatic Heterocycles from Ruthenium Tris(2-pyridylmethyl)amine with Visible Light.

Li A, White JK, Arora K, Herroon MK, Martin PD, Schlegel HB, Podgorski I, Turro C, Kodanko JJ.

Inorg Chem. 2016 Jan 4;55(1):10-2. doi: 10.1021/acs.inorgchem.5b02600. Epub 2015 Dec 15.

20.

Taxonomy proposal for Old World monkey adenoviruses: characterisation of several non-human, non-ape primate adenovirus lineages.

Pantó L, Podgorski II, Jánoska M, Márkó O, Harrach B.

Arch Virol. 2015 Dec;160(12):3165-77. doi: 10.1007/s00705-015-2575-z. Epub 2015 Sep 14.

PMID:
26370792
21.

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.

Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I.

Clin Exp Metastasis. 2015 Apr;32(4):353-68. doi: 10.1007/s10585-015-9714-5. Epub 2015 Mar 24.

22.

Adipose tissue dysfunction and its effects on tumor metabolism.

Diedrich J, Gusky HC, Podgorski I.

Horm Mol Biol Clin Investig. 2015 Jan;21(1):17-41. doi: 10.1515/hmbci-2014-0045. Review.

23.

Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound.

Respondek T, Sharma R, Herroon MK, Garner RN, Knoll JD, Cueny E, Turro C, Podgorski I, Kodanko JJ.

ChemMedChem. 2014 Jun;9(6):1306-15. doi: 10.1002/cmdc.201400081. Epub 2014 Apr 11.

24.

Ruthenium tris(2-pyridylmethyl)amine as an effective photocaging group for nitriles.

Sharma R, Knoll JD, Martin PD, Podgorski I, Turro C, Kodanko JJ.

Inorg Chem. 2014 Apr 7;53(7):3272-4. doi: 10.1021/ic500299s. Epub 2014 Mar 24.

25.

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Lopez-Gordo E, Podgorski II, Downes N, Alemany R.

Hum Gene Ther. 2014 Apr;25(4):285-300. doi: 10.1089/hum.2013.228. Epub 2014 Mar 25. Review.

26.

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I.

Cancer Metastasis Rev. 2014 Sep;33(2-3):527-43. doi: 10.1007/s10555-013-9484-y. Review.

27.

Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.

Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, Podgorski I.

Oncotarget. 2013 Nov;4(11):2108-23.

28.

IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.

Hardaway AL, Podgorski I.

Future Med Chem. 2013 Jun;5(10):1089-108. doi: 10.4155/fmc.13.90.

29.

Macrophage cathepsin K promotes prostate tumor progression in bone.

Herroon MK, Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorski I.

Oncogene. 2013 Mar 21;32(12):1580-93. doi: 10.1038/onc.2012.166. Epub 2012 May 21.

30.

Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru(II)(bpy)2.

Respondek T, Garner RN, Herroon MK, Podgorski I, Turro C, Kodanko JJ.

J Am Chem Soc. 2011 Nov 2;133(43):17164-7. doi: 10.1021/ja208084s. Epub 2011 Oct 12.

31.
32.

Chiral porphyrazine near-IR optical imaging agent exhibiting preferential tumor accumulation.

Trivedi ER, Harney AS, Olive MB, Podgorski I, Moin K, Sloane BF, Barrett AG, Meade TJ, Hoffman BM.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1284-8. doi: 10.1073/pnas.0912811107. Epub 2009 Dec 23.

33.

Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.

Jedeszko C, Victor BC, Podgorski I, Sloane BF.

Cancer Res. 2009 Dec 1;69(23):9148-55. doi: 10.1158/0008-5472.CAN-09-1043. Epub 2009 Nov 17.

34.

Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF.

Am J Pathol. 2009 Sep;175(3):1255-69. doi: 10.2353/ajpath.2009.080906. Epub 2009 Aug 21.

35.

Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?

Podgorski I, Linebaugh BE, Sloane BF.

Biochem Soc Trans. 2007 Aug;35(Pt 4):701-3. Review.

PMID:
17635127
36.

Loss of caspase-8 in tumor cells: mechanism to overcome integrin-mediated death?

Podgorski I, Sloane BF.

Mol Interv. 2006 Jun;6(3):132-6. No abstract available.

PMID:
16809473
37.

Functional imaging of tumor proteolysis.

Sloane BF, Sameni M, Podgorski I, Cavallo-Medved D, Moin K.

Annu Rev Pharmacol Toxicol. 2006;46:301-15. Review.

PMID:
16402907
38.

Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.

Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML, Sloane BF.

Neoplasia. 2005 Mar;7(3):207-23.

39.

Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment.

Sloane BF, Yan S, Podgorski I, Linebaugh BE, Cher ML, Mai J, Cavallo-Medved D, Sameni M, Dosescu J, Moin K.

Semin Cancer Biol. 2005 Apr;15(2):149-57. Epub 2004 Dec 30. Review.

PMID:
15652460
40.

Cathepsin B and its role(s) in cancer progression.

Podgorski I, Sloane BF.

Biochem Soc Symp. 2003;(70):263-76. Review.

PMID:
14587299
41.
42.

13-hydroxy- and 13-oxooctadecadienoic acids: novel substrates for human UDP-glucuronosyltransferases.

Jude AR, Little JM, Bull AW, Podgorski I, Radominska-Pandya A.

Drug Metab Dispos. 2001 May;29(5):652-5.

43.

Specific protein targets of 13-oxooctadecadienoic acid (13-OXO) and export of the 13-OXO-glutathione conjugate in HT-29 cells.

Blackburn ML, Podgorski I, Bull AW.

Biochim Biophys Acta. 1999 Sep 22;1440(2-3):225-34.

PMID:
10521706

Supplemental Content

Loading ...
Support Center